AVALO THERAPEUTICS INC (AVTX)
Health Care · biotechnology · NASDAQ
A clinical-stage biotechnology company developing targeted monoclonal antibody therapies for immunology and inflammatory conditions.
What AVALO THERAPEUTICS INC does
Avalo Therapeutics is a clinical-stage biotechnology company focused on the development of targeted therapies for immunological and inflammatory diseases. Its pipeline primarily consists of clinical-stage monoclonal antibodies and therapeutic candidates aimed at modulating the immune system.
Themes: immunology, drug discovery, inflammatory disease therapies, clinical-stage biotech
Fundamentals
- Price$13.43 as of 2026-10-08 close
- Market cap$720M as of 2026-08-03 (share count; price 2026-10-08)
- 1-year return-5.6% 2025-10-08 close $14.22 → 2026-10-08 close $13.43
- P/En/a negative earnings
- Net margin-132642.4% FY2025, SEC XBRL
- ROE-94.2% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Revenue growth (YoY)-86.6% as of 2026-09-03
- Revenue CAGR (3y)-85.2% SEC XBRL
- Beta0.86 as of 2026-09-03
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How AVTX compares in its sector
- net profit marginbottom 10% 430 covered Health Care peers, as of 2026-09-03
- operating marginbottom 10% 417 covered Health Care peers, as of 2026-09-03
- return on equitybottom 25% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How AVALO THERAPEUTICS INC looks technically
AVALO THERAPEUTICS INC (AVTX) is trading 19.3% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 74 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 40, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 27, in oversold territory (below 30). It just made a new 20-day low, its first since 2026-06-10, breaking below its recent trading range. It is 44.7% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 19.3% below its 200-day average, the long-term trend line — a long-term downtrend | -19.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $17.73 | $17.73 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $16.63 | $16.63 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 18.88. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible downward five-wave sequence, in wave 4 |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 74 trading days ago — a "golden cross", a bullish long-term signal | 74 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 40, with sellers in control | 39.7 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 27, in oversold territory (below 30) | 26.7 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($12.77 to $16.86) — its "stochastic" reading is 16 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 16.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 29 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $24.27 | $24.27 |
|---|---|---|
| From the 52-week high | it is 44.7% below its 52-week high (its highest price of the past year) | -44.7% |
| Above the 52-week low | it is 7.4% above its 52-week low (its lowest price of the past year) | +7.3% |
| Below the 52-week high | it is 44.7% below its highest point of the past year | 44.7% |
| Since a 20-day breakout | it just made a new 20-day low, its first since 2026-06-10, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day low, its first since 2026-06-10, breaking below its recent trading range | 1 session |
| All-time high | its highest closing price on record is $22032.00 (set on 2019-02-27) | $22032.00 |
| Given back of the 52-week move | over the past year its closes ranged ($12.74 to $22.87), and it has recovered only a small part of its fall from last year’s high — 7% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $19.00 to $19.32. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 6.8% |
| From the all-time high | it is 99.9% below its all-time high | -99.9% |
| Nearest price level | it is trading 1.1% below a resistance level at $13.57 — a price it turned at twice since 2024-11-14, most recently on 2026-02-23. Since 2024-10-08 it has 8 such levels below the current price and 8 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.1% |
| All-time low | its lowest closing price on record is $3.39 (set on 2025-05-14) | $3.39 |
| Above the all-time low | it is 296.2% above its all-time low | +296.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 35th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.9401 between its high and its low — about 7.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.9401 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $13.45 and $17.40 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $13.45 – $15.43 – $17.40 |
| Typical daily range (% of price) | its price moves about 7.0% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.0% |
| Stretch from the 200-day average | it is trading 3.4 daily ranges below its 200-day average price (19.3% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.4 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.93× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a hammer | 4 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 4 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 1.0% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.0% |
|---|---|---|
| Gap filled | a 3.2% gap up opened on 2026-09-17 has been "filled" 15 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 15 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 4 sessions in a row, a -10.41% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 4 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 32.9 percentage points (the stock lost 31.9% while the market gained 1.0%) | -32.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 33.9 percentage points (the stock lost 30.1% while the market gained 3.8%) | -33.9% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 34.9 percentage points (the stock lost 17.5% while the market gained 17.5%) | -34.9% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 20.5 percentage points (the stock lost 5.6% while the market gained 15.0%) | -20.5% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, its RSI momentum gauge is oversold (a beaten-down reading), near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 24% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 14.7% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -23.9% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 23% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $17.34 — a volume-weighted average of daily closes over 192 sessions, not a true tick-by-tick VWAP. | -22.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 22% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $17.25 — a volume-weighted average of daily closes over 45 sessions, not a true tick-by-tick VWAP. | -22.1% |
Price levels it has turned at before
AVTX last closed at $13.43 on 2026-10-08. Since 2024-10-08 it has turned at 8 prices below its last close and 8 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $13.57 | Resistance | 1.1% above the last close | turned there twice · 2024-11-14 to 2026-02-23 |
| $13.12 | Support | 2.3% below the last close | turned there four times · 2025-10-13 to 2026-04-14 |
| $12.48 | Support | 7.1% below the last close | turned there three times · 2025-09-05 to 2026-06-09 |
| $12.00 | Support | 10.7% below the last close | turned there twice · 2024-11-08 to 2024-12-10 |
| $15.28 | Resistance | 13.8% above the last close | turned there four times · 2026-01-05 to 2026-09-15 |
| $15.99 | Resistance | 19.1% above the last close | turned there twice · 2024-10-28 to 2025-10-08 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $18.88.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $15.97 and $17.54 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 3 trading days, since 2026-10-06.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Oversold (14-day RSI below 30) · Pulled back from the 12-month high · Broke down to a new 20-day low · lagging the market · Printed a doji candle | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.14 mean, 1=Strong Buy…5=Strong Sell) — 12 analysts
- Mean price target$44.08 range $30.00 – $60.00; median $40.50
Analyst estimates, as of 2026-10-06. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for AVTX
- Consensus EPS estimate-$0.5625 next reporting period, as of 2026-10-06
- Estimate change, 30 days-$0.06139 from -$0.5011, on 2026-09-01, 35-day window
- Readings revised upward0% of 5 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant history of operating losses and dependence on additional capital to fund clinical trials.","Risks associated with the success and regulatory approval of clinical-stage drug candidates.","Potential volatility and dilution for stockholders due to financing activities and complex capital structures."]
What changed in the latest 10-Q
AI-assisted comparison of AVTX's 10-Q filed 2026-08-06 against the prior one filed 2026-05-13.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (filed 2026-08-06) states Avalo is advancing abdakibart into a phase 3 registrational program in hidradenitis suppurativa.
- Newer filing (filed 2026-08-06) states abdakibart demonstrated statistically significant benefit across the key secondary endpoints, including HiSCR50, change in IHS4, and change in draining tunnel count.
- Newer filing (filed 2026-08-06) states AVTX-010, a long-acting next-generation anti-IL-1β mAb, is being developed.
- Newer filing (filed 2026-08-06) states an equity offering was completed in the second quarter of 2026 for net proceeds of $405.0 million.
- Newer filing (filed 2026-08-06) states Ron Philip was appointed to the Board of Directors in June 2026.
- Newer filing (filed 2026-08-06) reports six-month net loss of $56.0 million and negative cash flows from operations of $37.7 million for the six months ended June 30, 2026.
- Newer filing (filed 2026-08-06) reports cash, cash equivalents and investments of $472.2 million as of June 30, 2026.
- Removed:
- Older filing (filed 2026-05-13) states positive topline data was recently reported for abdakibart in a Phase 2 clinical trial in hidradenitis suppurativa without specifying advancement into phase 3.
- Older filing (filed 2026-05-13) states numerically favorable responder rates were observed across all other key secondary endpoints.
- Older filing (filed 2026-05-13) states the HiSCR75 response was similar in patients with and without prior biologic exposure.
- Older filing (filed 2026-05-13) states the highest absolute improvement in HiSCR75 and HiSCR50 in clinical trials of this size or larger was observed at each individual dose and on a combined dose basis.
- Older filing (filed 2026-05-13) describes the LOTUS trial design with 253 adults, dosing regimens, and endpoint definition in the MD&A text.
- Older filing (filed 2026-05-13) states on April 26, 2026 the Company entered into a Milestone Buyout Option and Amendment Agreement with AlmataBio, including the $2.25 million upfront payment.
- Older filing (filed 2026-05-13) states May 7, 2026 follow-on offering details including shares, pre-funded warrants, public offering price, and aggregate gross proceeds of approximately $431.3 million.
- Older filing (filed 2026-05-13) reports three-month net loss of $19.6 million and negative cash flows from operations of $17.7 million for the three months ended March 31, 2026.
- Older filing (filed 2026-05-13) reports cash and cash equivalents and short-term investments of $82.0 million as of March 31, 2026.
- Reworded:
- Overview changed from 'fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases' (filed 2026-05-13) to 'dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases' (filed 2026-08-06).
- Lead asset description changed from 'abidakibart (AVTX-009)' (filed 2026-05-13) to 'abidakibart' without the AVTX-009 parenthetical (filed 2026-08-06).
- Cash runway language changed from 'sufficient to fund operations for at least twelve months from the filing date... and into 2029' (filed 2026-05-13) to 'sufficient to fund operations into 2029' (filed 2026-08-06).
- Notes:
- The newer MD&A text appears truncated at 'manufacturing process validation, p' and the older MD&A text appears truncated at 'relative to the availa', so any changes after those points in the section cannot be assessed.
Risk Factors
- Added:
- The newer filing (filed 2026-08-06) added disclosure in Item 2(a) about the AlmataBio Buyout Agreement, including an upfront payment of $2.25 million, an option to pay $5.125 million in lieu of the $15.0 million Phase 3 Milestone, payment of $2.6 million and issuance of 128,189 shares of common stock on June 3, 2026.
- The newer filing (filed 2026-08-06) added a Director and Officer Trading Plans and Arrangements section under Item 5(c) disclosing 10b5-1 trading arrangements for Garry Neil (adopted May 28, 2026), Christopher Sullivan (modified May 18, 2026), and Paul Varki (terminated May 13, 2026).
- The newer filing (filed 2026-08-06) added exhibit 3.1 (Certificate of Designation for Series C-1 Preferred Stock filed June 11, 2026).
- The newer filing (filed 2026-08-06) added exhibits 10.1-10.7 covering amendments to executive agreements and an amended employee stock purchase plan.
- The newer filing (filed 2026-08-06) added exhibit 21.1 (List of Subsidiaries).
- The newer filing (filed 2026-08-06) added a signature date of August 6, 2026.
- Removed:
- The older filing (filed 2026-05-13) contained exhibit 10.1** (Milestone Buyout Option Agreement and Amendment to Agreement and Plan of Merger and Reorganization, effective April 26, 2026), which is not listed in the newer filing's exhibits.
- The older filing (filed 2026-05-13) had a signature date of May 13, 2026.
- Reworded:
- The newer filing (filed 2026-08-06) revised the Item 5 header from 'Insider Trading Arrangements' (in the older filing) to 'Other Information' with subsection '(c) Director and Officer Trading Plans and Arrangements'.
- The older filing (filed 2026-05-13) stated no director or officer adopted, modified, or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement during the quarter ended March 31, 2026; the newer filing (filed 2026-08-06) disclosed three such arrangements during the quarter ended June 30, 2026.
- The newer filing (filed 2026-08-06) expanded the Interactive Data Files exhibit description to cover periods ended June 30, 2026 and 2025, whereas the older filing covered periods ended March 31, 2026 and 2025.
- Notes:
- The sections provided include Items 2-6 and signatures in addition to the Risk Factors text; the quoted Risk Factors language itself (incorporating by reference the 2025 10-K) is identical between the two filings.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 10 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 2 sells ($381894) — 1 selling insider
- Last 90 days · read to 2026-10-040 buys · 10 sells ($2M) — 3 selling insiders
- Last 180 days · read to 2026-10-040 buys · 34 sells ($8M) — 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-16. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about AVTX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding AVTX as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 13,612,722
- Reported value $251,563,102
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 5 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about AVTX's institutional holders → See what each manager we track holds →
Short interest (FINRA)
AVTX had 12,925,869 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
AVTX had 24.1% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 13.24 days to cover at the same settlement.
- Reported short interest (shares) 12,925,869
- Short interest (% of shares outstanding) 24.1%
- Prior settlement (shares) 12,387,012
- Reported change 4.35%
- Days to cover (reported) 13.24
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Amgen (AMGN)
- Regeneron Pharmaceuticals (REGN)
- AbbVie (ABBV)
- Bristol Myers Squibb (BMY)
- Eli Lilly (LLY)
- Novartis (NVS)
- Roche (RHHBY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AVTX vs…
AVALO THERAPEUTICS INC is found in…
Frequently asked questions
What does AVALO THERAPEUTICS INC (AVTX) do?
Avalo Therapeutics is a clinical-stage biotechnology company focused on the development of targeted therapies for immunological and inflammatory diseases. Its pipeline primarily consists of clinical-stage monoclonal antibodies and therapeutic candidates aimed at modulating the immune system.
What sector is AVALO THERAPEUTICS INC (AVTX) in?
AVALO THERAPEUTICS INC (AVTX) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are AVALO THERAPEUTICS INC's (AVTX) competitors?
Notable peers of AVALO THERAPEUTICS INC (AVTX) include Amgen, Regeneron Pharmaceuticals, AbbVie, Bristol Myers Squibb and Eli Lilly. This peer set is informational only — not financial advice.
Is AVALO THERAPEUTICS INC (AVTX) overbought or oversold right now?
AVALO THERAPEUTICS INC (AVTX) is currently in oversold territory (its 14-day RSI is 27, below 30) (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AVTX come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.